Immunicon Report issue

For profit Phase 3
Founded: Huntingdon Valley PA United States (1983)
Status: Defunct (2008)

Organization Overview

First Clinical Trial
2005
NCT00208546
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Immunicom Inc

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Colorectal Neoplasms (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 4